Technical Analysis for AEZS - AEterna Zentaris Inc.

Grade Last Price % Change Price Change
grade A 3.54 -6.84% -0.26
AEZS closed down 6.84 percent on Friday, January 18, 2019, on 72 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical AEZS trend table...

Date Alert Name Type % Chg
Jan 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -6.84%
Jan 17 Calm After Storm Range Contraction -6.84%
Jan 17 Upper Bollinger Band Walk Strength -6.84%
Jan 17 Inside Day Range Contraction -6.84%
Jan 17 Wide Bands Range Expansion -6.84%
Jan 17 Overbought Stochastic Strength -6.84%
Jan 16 Bearish Engulfing Bearish -1.67%
Jan 16 Volume Surge Other -1.67%

Older signals for AEZS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company's product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company's products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
Is AEZS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.14
52 Week Low 1.12
Average Volume 547,663
200-Day Moving Average 2.1302
50-Day Moving Average 3.0706
20-Day Moving Average 3.2565
10-Day Moving Average 3.623
Average True Range 0.2959
ADX 24.54
+DI 24.5321
-DI 18.3381
Chandelier Exit (Long, 3 ATRs ) 3.2523
Chandelier Exit (Short, 3 ATRs ) 3.3577
Upper Bollinger Band 4.117
Lower Bollinger Band 2.396
Percent B (%b) 0.66
BandWidth 52.84815
MACD Line 0.2226
MACD Signal Line 0.191
MACD Histogram 0.0316
Fundamentals Value
Market Cap 57.04 Million
Num Shares 16.1 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -2.07
Price-to-Sales 28.12
Price-to-Book 6.12
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.04
Resistance 3 (R3) 4.08 3.97 3.95
Resistance 2 (R2) 3.97 3.84 3.94 3.92
Resistance 1 (R1) 3.75 3.76 3.70 3.71 3.90
Pivot Point 3.64 3.64 3.61 3.61 3.64
Support 1 (S1) 3.42 3.51 3.37 3.38 3.18
Support 2 (S2) 3.31 3.43 3.28 3.16
Support 3 (S3) 3.09 3.31 3.13
Support 4 (S4) 3.05